FDA Approves Expanded Indication for Merck ’s Keytruda (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

KENILWORTH, N.J.--(BUSINESS WIRE) October 15, 2020 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news